Amalgamated Bank Reduces Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Amalgamated Bank reduced its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 4.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,380 shares of the medical instruments supplier’s stock after selling 703 shares during the period. Amalgamated Bank’s holdings in West Pharmaceutical Services were worth $5,066,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of WST. Fidelis Capital Partners LLC acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at approximately $27,000. Crewe Advisors LLC grew its stake in West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares in the last quarter. Quarry LP increased its holdings in West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. acquired a new stake in West Pharmaceutical Services during the first quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services during the first quarter worth $40,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Down 1.0 %

WST stock opened at $308.15 on Friday. The firm has a market cap of $22.45 billion, a price-to-earnings ratio of 40.99, a PEG ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The firm has a fifty day moving average price of $303.67 and a two-hundred day moving average price of $337.77. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period last year, the company posted $2.11 earnings per share. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

Insider Buying and Selling

In other news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now directly owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.